Mechanisms of Resistance to BCR-ABL Kinase Inhibitors
Since the introduction of imatinib mesylate for the treatment of chronic myeloid leukaemia, impressive clinical responses were observed in the majority of patients in chronic phase. However, not all patients experience an optimal response to imatinib mesylate or even to the more potent, second gener...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | article |
| Language: | por |
| Published: |
2013
|
| Online Access: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4812 |
| Country: | Portugal |
| Oai: | oai:ojs.www.actamedicaportuguesa.com:article/4812 |